argenx Financials - Benzinga

argenx SE

ARGXNASDAQ

Trade with Public

Trade with Public

$958.29

-13.96-1.44%

Últ. Act.: Sep 29, 11:23 AM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

argenx Financials

argenx (ARGX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Earnings Scheduled For July 23, 2026

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report

Benzinga Insights

PRO
argenx Q2 EPS $7.32 Beats $6.24 Estimate, Sales $1.542B Beat $1.442B Estimate

argenx (NASDAQ:ARGX) reported quarterly earnings of $7.32 per share which beat the analyst consensus estimate of $6.24 by 17.31 percent. This is a 95.72 percent increase over earnings of $3.74 per share from the same

Benzinga Newsdesk

PRO
argenx Q1 EPS $5.52 Beats $5.42 Estimate, Sales $1.313B Miss $1.314B Estimate

argenx (NASDAQ:ARGX) reported quarterly earnings of $5.52 per share which beat the analyst consensus estimate of $5.42 by 1.85 percent. This is a 113.95 percent increase over earnings of $2.58 per share from the same

Benzinga Newsdesk

These Analysts Revise Their Forecasts On Argenx After Q4 Earnings

Avi Kapoor

Argenx Touts Positive Phase 3 Eye Disease Study Results

Argenx reports positive Phase 3 results for Vyvgart in eye disease, beats earnings as sales surge over 70%.

Vandana Singh

Earnings Scheduled For February 26, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved